ID

21231

Descrizione

Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00363779

collegamento

https://clinicaltrials.gov/show/NCT00363779

Keywords

versioni (2)
  1. 13/04/17 13/04/17 -
  2. 13/04/17 13/04/17 -
Caricato su

13 aprile 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Large Granular Lymphocytic Leukemia NCT00363779

Inglese

Eligibility Large Granular Lymphocytic Leukemia NCT00363779

1 moduli  
Criteria
Descrizione

Criteria

1. all patients must have a histologic or cytologic diagnosis of t-cell lgl leukemia as determined by the laboratory of pathology or hematology at the clinical center, national institutes of health
Descrizione

T-Cell Large Granular Lymphocyte Leukemia

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1955861
2. all patients must have hemocytopenias such as granulocyte count less than 1,200/ul, platelet count less than 100,000/ul or hemoglobin less than 10 g/dl, or require hematopoietic support (transfusion or colony stimulating factors) to maintain counts at these or higher levels.
Descrizione

Hemocytes Count Decreased | Granulocyte count | Platelet Count measurement | Hemoglobin measurement | Support Hematopoietic Patient need for | Blood Transfusion | Colony-Stimulating Factors

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0019000
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C0205216
UMLS CUI [2]
C0857490
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0518015
UMLS CUI [5,1]
C1521721
UMLS CUI [5,2]
C0229601
UMLS CUI [5,3]
C0686904
UMLS CUI [6]
C0005841
UMLS CUI [7]
C0009392
3. patients must have measurable or evaluable disease
Descrizione

Measurable Disease | Evaluable Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2]
C1516986
4. patients must have a creatinine of less than 2.0 mg/dl.
Descrizione

Creatinine measurement, serum

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0201976
5. omission of cytotoxic chemotherapy for 3 weeks prior to entry into the trial is required. however, patients receiving stable corticosteroids will be eligible.
Descrizione

Cytotoxic Chemotherapy Omission | Adrenal Cortex Hormones Stable

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C3845736
UMLS CUI [2,1]
C0001617
UMLS CUI [2,2]
C0205360
6. age greater than 18 years
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
7. karnofsky performance greater than 70%
Descrizione

Karnofsky Performance Status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0206065
8. patients must have a life expectancy of greater than 3 months.
Descrizione

Life Expectancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023671
9. patients must be able to understand and sign an informed consent form.
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
10. all female patients must use adequate contraception during participation in this trial and for three months after completing therapy.
Descrizione

Gender Contraceptive methods

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0700589
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. patients with uncontrolled hypertension
Descrizione

Uncontrolled hypertension

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1868885
2. pregnant and nursing patients are not eligible for the study as csa crosses the placenta. based on clinical use, premature births and low birth weight were consistently observed. breast-feeding is contraindicated because csa enters the blood milk and may possibly be administered to the child.
Descrizione

Pregnancy | Breast Feeding | Cyclosporine | Premature Birth | Low Birth Weight

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0010592
UMLS CUI [4]
C0151526
UMLS CUI [5]
C0024032
3. underlying immunodeficiency state including human immunodeficiency virus (hiv) seropositivity.
Descrizione

Immunodeficiency | HIV Seropositivity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021051
UMLS CUI [2]
C0019699
4. positive for antibodies to hepatitis c or positive for hepatitis b surface antigen,
Descrizione

Hepatitis C antibody positive | Hepatitis B surface antigen positive

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0281863
UMLS CUI [2]
C0149709
5. patients with serious intercurrent illnesses, concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious or metabolic disease of such severity that it would preclude the patients' ability to tolerate cyclosporine.
Descrizione

Comorbidity Serious Excludes Cyclosporine | Liver disease | Kidney Disease | Heart Disease | nervous system disorder | Lung disease | Communicable Disease | Metabolic Disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0332196
UMLS CUI [1,4]
C0010592
UMLS CUI [2]
C0023895
UMLS CUI [3]
C0022658
UMLS CUI [4]
C0018799
UMLS CUI [5]
C0027765
UMLS CUI [6]
C0024115
UMLS CUI [7]
C0009450
UMLS CUI [8]
C0025517
6. patients who received cyclosporine for lgl leukemia previously and failed to respond.
Descrizione

Cyclosporine | Large Granular Lymphocytic Leukemia Absent response to treatment

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0010592
UMLS CUI [2,1]
C1522378
UMLS CUI [2,2]
C0438286
Ritorna all'inizio della pagina

Similar models

Eligibility Large Granular Lymphocytic Leukemia NCT00363779

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
T-Cell Large Granular Lymphocyte Leukemia
Item
1. all patients must have a histologic or cytologic diagnosis of t-cell lgl leukemia as determined by the laboratory of pathology or hematology at the clinical center, national institutes of health
boolean
C1955861 (UMLS CUI [1])
Hemocytes Count Decreased | Granulocyte count | Platelet Count measurement | Hemoglobin measurement | Support Hematopoietic Patient need for | Blood Transfusion | Colony-Stimulating Factors
Item
2. all patients must have hemocytopenias such as granulocyte count less than 1,200/ul, platelet count less than 100,000/ul or hemoglobin less than 10 g/dl, or require hematopoietic support (transfusion or colony stimulating factors) to maintain counts at these or higher levels.
boolean
C0019000 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0205216 (UMLS CUI [1,3])
C0857490 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0518015 (UMLS CUI [4])
C1521721 (UMLS CUI [5,1])
C0229601 (UMLS CUI [5,2])
C0686904 (UMLS CUI [5,3])
C0005841 (UMLS CUI [6])
C0009392 (UMLS CUI [7])
Measurable Disease | Evaluable Disease
Item
3. patients must have measurable or evaluable disease
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
Creatinine measurement, serum
Item
4. patients must have a creatinine of less than 2.0 mg/dl.
boolean
C0201976 (UMLS CUI [1])
Cytotoxic Chemotherapy Omission | Adrenal Cortex Hormones Stable
Item
5. omission of cytotoxic chemotherapy for 3 weeks prior to entry into the trial is required. however, patients receiving stable corticosteroids will be eligible.
boolean
C0677881 (UMLS CUI [1,1])
C3845736 (UMLS CUI [1,2])
C0001617 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
Age
Item
6. age greater than 18 years
boolean
C0001779 (UMLS CUI [1])
Karnofsky Performance Status
Item
7. karnofsky performance greater than 70%
boolean
C0206065 (UMLS CUI [1])
Life Expectancy
Item
8. patients must have a life expectancy of greater than 3 months.
boolean
C0023671 (UMLS CUI [1])
Informed Consent
Item
9. patients must be able to understand and sign an informed consent form.
boolean
C0021430 (UMLS CUI [1])
Gender Contraceptive methods
Item
10. all female patients must use adequate contraception during participation in this trial and for three months after completing therapy.
boolean
C0079399 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Uncontrolled hypertension
Item
1. patients with uncontrolled hypertension
boolean
C1868885 (UMLS CUI [1])
Pregnancy | Breast Feeding | Cyclosporine | Premature Birth | Low Birth Weight
Item
2. pregnant and nursing patients are not eligible for the study as csa crosses the placenta. based on clinical use, premature births and low birth weight were consistently observed. breast-feeding is contraindicated because csa enters the blood milk and may possibly be administered to the child.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0010592 (UMLS CUI [3])
C0151526 (UMLS CUI [4])
C0024032 (UMLS CUI [5])
Immunodeficiency | HIV Seropositivity
Item
3. underlying immunodeficiency state including human immunodeficiency virus (hiv) seropositivity.
boolean
C0021051 (UMLS CUI [1])
C0019699 (UMLS CUI [2])
Hepatitis C antibody positive | Hepatitis B surface antigen positive
Item
4. positive for antibodies to hepatitis c or positive for hepatitis b surface antigen,
boolean
C0281863 (UMLS CUI [1])
C0149709 (UMLS CUI [2])
Comorbidity Serious Excludes Cyclosporine | Liver disease | Kidney Disease | Heart Disease | nervous system disorder | Lung disease | Communicable Disease | Metabolic Disease
Item
5. patients with serious intercurrent illnesses, concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious or metabolic disease of such severity that it would preclude the patients' ability to tolerate cyclosporine.
boolean
C0009488 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0332196 (UMLS CUI [1,3])
C0010592 (UMLS CUI [1,4])
C0023895 (UMLS CUI [2])
C0022658 (UMLS CUI [3])
C0018799 (UMLS CUI [4])
C0027765 (UMLS CUI [5])
C0024115 (UMLS CUI [6])
C0009450 (UMLS CUI [7])
C0025517 (UMLS CUI [8])
Cyclosporine | Large Granular Lymphocytic Leukemia Absent response to treatment
Item
6. patients who received cyclosporine for lgl leukemia previously and failed to respond.
boolean
C0010592 (UMLS CUI [1])
C1522378 (UMLS CUI [2,1])
C0438286 (UMLS CUI [2,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial